Australia markets close in 57 minutes

Fulgent Genetics, Inc. (FLGT)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
33.78+0.74 (+2.24%)
At close: 04:00PM EST
34.05 +0.27 (+0.80%)
After hours: 07:53PM EST

Fulgent Genetics, Inc.

4978 Santa Anita Avenue
Temple City, CA 91780
United States
626 350 0537

IndustryDiagnostics & Research
Full-time employees645

Key executives

NameTitlePayExercisedYear born
Mr. Ming HsiehChairman & CEO5.66MN/A1956
Mr. Jian XieCOO & Pres704.62kN/A1966
Mr. Paul KimChief Financial Officer669.98kN/A1967
Dr. Han Lin Gao D.A.B.M.G., F.A.C.M.G., FACMG, M.D., Ph.D.Chief Scientific Officer & Laboratory Director630.54kN/A1967
Ms. Natalie PrescottVP of Legal & Deputy Gen. CounselN/AN/AN/A
Ms. Doreen NgVP of Operations & Compliance and GM of Houston OfficeN/AN/AN/A
Mr. Jakub SramVP of Bus. Devel. & SalesN/AN/AN/A
Ms. Ellen TsuiVP of HRN/AN/AN/A
Mr. Brandon PerthuisChief Commercial OfficerN/AN/AN/A
Dr. Lawrence M. Weiss M.D.Chief Medical OfficerN/AN/A1957
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.

Corporate governance

Fulgent Genetics, Inc.’s ISS governance QualityScore as of 28 January 2023 is 7. The pillar scores are Audit: 7; Board: 9; Shareholder rights: 4; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.